<DOC>
	<DOCNO>NCT00277667</DOCNO>
	<brief_summary>The purpose research study evaluate safety , tolerability , efficacy quetiapine compare placebo ( sugar pill without medication ) treatment bipolar disorder moderate severe hypomania mild mania . Quetiapine approve United States Food Drug Administration ( FDA ) treatment schizophrenia bipolar mania .</brief_summary>
	<brief_title>Study Quetiapine Monotherapy Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms Mild Manic Symptoms</brief_title>
	<detailed_description>Methods Procedures This single center , eight-week , randomize , double-blind , placebo-controlled , parallel group , flexible-dose study 40 outpatient bipolar disorder type I , II , NOS DSM-IV-TR criterion also moderate-to-severe hypomanic symptom mild manic symptom ( define score &gt; 3 &lt; 5 Clinical Global Impressions Scale Modified Bipolar Disorder [ CGI-BP ] ) . Subjects may concurrent depressive anxiety symptom syndrome , may psychotic feature ( define DSM-IV ) substance dependence . The primary outcome measure change Young Mania Rating Scale ( YMRS ) score . Secondary outcome measure include total YMRS Inventory Depressive Symptoms ( IDS ) , IDS alone , Hamilton Rating Scale Anxiety ( HAM-A ) , CGI-BP , Global Assessment Functioning ( GAF ) , Life Functioning Questionnaire ( LFQ ) , Sheehan Disability Scale ( DSD ) . Of note , YMRS-IDS total reflect novel mean assess total affective burden . Also , IDS use assess depressive symptom experience Stanley Foundation Bipolar Network indicate scale well assess sign symptom bipolar depression compare Hamilton Rating Scale Depression ( HAM-D ) Montgomery-Asberg Depression Scale ( MADRAS ) . The LFQ validate gender neutral scale specifically design assess functional outcome bipolar disorder . The Abnormal Involuntary Movement Scale ( AIMS ) , Simpson Angus Scale ( SAS ) , Barnes Akathisia Scale ( BARS ) , use assess degree severity extrapyramidal side effect experience . Data Analysis Data Monitoring All subject observation available baseline least one post-baseline visit include analysis . The primary outcome measure change YMRS scale score baseline last observation . The difference YMRS change treatment group test significance ( alpha=0.05 , two-tailed ) use independent-samples t-test . Measures change total affective burden , depressive anxiety symptom , global improvement , use adjunctive anxiolytic hypnotic medication , adherence study medication , frequency severity side effect , reason early termination also analyze . The final dose achieve subject correlate scale score change . Tolerability assess base adverse experience , clinical laboratory test , vital sign ( blood pressure pulse ) , weight , discontinuation rate .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Subjects must 18 year age old . 2 . Subjects must bipolar I , II , otherwise specify ( NOS ) disorder define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion . Of note , bipolar NOS disorder include subject either recurrent sporadic brief hypomanias ( hypomanias 1 3 day duration ) . 3 . Subjects must moderatetosevere hypomanic symptom mild manic symptom must clinically significant ( least mild ) worse moderately severe , defined CGIBP scale mania &gt; 3 &lt; 5 , least 2 assessment day least 3 day apart screen phase . 4 . Subjects must receive mood stabilizing , antidepressant , antipsychotic medication &gt; one week . 5 . Subjects legally authorize representative must sign Informed Consent document nature trial fully explain . 6 . If female , subject must : postmenopausal , surgically incapable childbearing , practice medically acceptable , effective method ( ) contraception ( e.g. , hormonal method , intrauterine device ) least one month prior study entry throughout study . Criteria exclusion study follow : 1 . Subjects bipolar disorder DSMIVTR criterion . 2 . Subjects receive treatment antimanic mood stabilize medication ( lithium , valproate , carbamazepine , antipsychotic ) , investigator ' judgment , require ongoing treatment medication . 3 . Subjects whose bipolar manic symptom presently less mild ( CGIBP &lt; 2 ) markedly ill ( CGIBP &gt; 5 YMRS &gt; 21 ) 4 . Subjects severe depressive symptom ( IDS &gt; 39 ) psychotic feature ( defined DSMIV ) 5 . Subjects clinically significant suicidal homicidal ideation . 6 . Subjects current DSMIV Axis I diagnosis delirium , dementia , amnesia , cognitive disorder ; DSMIV diagnosis substance use disorder within past six month ; lifetime DSMIV psychotic disorder ( e.g. , schizophrenia schizoaffective disorder ) . 7 . Subjects serious general medical illness include hepatic , renal , respiratory , cardiovascular , endocrine , neurologic , hematologic disease determine clinical judgment clinical investigator . Subjects hypo hyperthyroidism unless stabilize thyroid replacement &gt; 3 month . 8 . Subjects allergic demonstrate hypersensitivity quetiapine . 9 . Women pregnant nursing . 10 . Subjects receive experimental drug use experimental device within 30 day . 11 . Subjects history neuroleptic malignant syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>currently experience hypomania mild mania</keyword>
</DOC>